Blueprint Medicines Corp Stock Analysis

Blueprint Stock Analysis Notes

About 99.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 2.09. Blueprint Medicines Corp had not issued any dividends in recent years. Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Blueprint Medicines operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 580 people. For more info on Blueprint Medicines Corp please contact Kathryn MBA at 617 374 7580 or go to https://www.blueprintmedicines.com.

Blueprint Medicines Corp Investment Alerts

Blueprint Medicines Corp Upcoming and Recent Events

Blueprint Largest EPS Surprises

View All Earnings Estimates

Blueprint Medicines Environmental, Social, and Governance (ESG) Scores

Blueprint Medicines Thematic Classifications

Blueprint Stock Institutional Investors

Note, although Blueprint Medicines' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Blueprint Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.04 B.

Blueprint Profitablity

The company has Profit Margin (PM) of (0.29) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.38) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.38.

Management Efficiency

Blueprint Medicines Corp has return on total asset (ROA) of (0.1497) % which means that it has lost $0.1497 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4966) %, meaning that it created substantial loss on money invested by shareholders. Blueprint Medicines' management efficiency ratios could be used to measure how well Blueprint Medicines manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.51. In addition to that, Return On Capital Employed is expected to decline to -0.61. At present, Blueprint Medicines' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 613.2 M, whereas Total Assets are forecasted to decline to about 784.9 M.

Technical Drivers

As of the 29th of November, Blueprint Medicines shows the Downside Deviation of 2.69, risk adjusted performance of 0.0261, and Mean Deviation of 1.81. Blueprint Medicines Corp technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Blueprint Medicines Corp Price Movement Analysis

Blueprint Medicines Corp Insider Trading Activities

Blueprint Medicines Outstanding Bonds

Blueprint Medicines Predictive Daily Indicators

Blueprint Medicines Corporate Filings

Blueprint Medicines Forecast Models

Blueprint Medicines' time-series forecasting models are one of many Blueprint Medicines' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Blueprint Medicines' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Blueprint Medicines prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Blueprint shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Blueprint Medicines. By using and applying Blueprint Stock analysis, traders can create a robust methodology for identifying Blueprint entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Blueprint analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Blueprint analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Blueprint Medicines Corp stock analysis indicators help investors evaluate how Blueprint Medicines stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Blueprint Medicines shares will generate the highest return on investment. By understating and applying Blueprint Medicines stock analysis, traders can identify Blueprint Medicines position entry and exit signals to maximize returns.

When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.